BRISBANE, Calif., June 21, 2019 /PRNewswire/
-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic
medicine company, today announced the upcoming presentation of data
from the Phase 1/2 Alta study evaluating investigational SB-525
gene therapy in patients with severe hemophilia A. The initial
results of the study will be reported in an oral presentation at
the XXVII Congress of the International Society on Thrombosis and
Haemostasis (ISTH), in Melbourne,
Australia, July 6-10, 2019.
SB-525 is being developed as part of a global collaboration between
Sangamo and Pfizer.
The presentation, "Initial results of the Alta study, a phase
1/2, open label, adaptive, dose-ranging study to assess the safety
and tolerability of SB-525 gene therapy in adult subjects with
severe hemophilia A," will take place on Saturday, July 6th, at 1:15 p.m. Australian Eastern Standard Time
(July 5th at 11:15 p.m. Eastern Daylight Time). The results
will be presented by Barbara Konkle,
MD, Bloodworks Northwest and Professor of Medicine at University of Washington, and Principal
Investigator of the Alta study.
The ISTH abstract was published today and is available here on
the ISTH website.
The SB-525 presentation at ISTH will expand upon interim results
announced by Sangamo and Pfizer on April 2,
2019 and will include longer-term follow-up data on the
first eight patients in the study including Factor VIII levels,
bleeding rates, Factor VIII replacement therapy usage, and safety.
Early data from the first two patients treated in the 3e13 vg/kg
expansion cohort will also be included in the presentation.
About the Alta study
The Phase 1/2 Alta study is an open-label, dose-ranging clinical
trial designed to assess the safety and tolerability of SB-525 in
adult patients with severe hemophilia A. The U.S. Food and Drug
Administration has granted Orphan Drug and Fast Track designations
to SB-525, which also received Orphan Medicinal Product designation
from the European Medicines Agency.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating
ground-breaking science into genomic medicines with the potential
to transform patients' lives. Our capabilities in gene therapy,
cell therapy, genome editing, and gene regulation allow us to apply
the appropriate therapeutic approach to the underlying genetic
cause of the disease. For more information about Sangamo, visit
www.sangamo.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sangamo-announces-upcoming-presentation-of-investigational-sb-525-hemophilia-a-gene-therapy-data-at-isth-2019-300872657.html
SOURCE Sangamo Therapeutics, Inc.